NCT07167160View on ClinicalTrials.gov

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions
Cervical CancerImmunochemotherapy
Interventions
DRUG

Camrelizumab combined with chemotherapy

Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery

Trial Locations (1)

310000

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Women's Hospital School Of Medicine Zhejiang University

OTHER